| Jason A Spector, MD | |
|
525 E 68th St, Suite M014, New York, NY 10021-4870 | |
| (212) 746-5593 | |
| (212) 746-8666 |
| Full Name | Jason A Spector |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 28 Years |
| Location | 525 E 68th St, New York, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124048178 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 208508 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian Hospital | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Weill Medical College Of Cornell | 6800709023 | 1616 |
News Archive
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
Researchers at Vanderbilt University Medical Center are leading an international clinical trial to examine the functional benefits of a combined therapy to treat acute ischemic stroke, a type of stroke where a blood clot becomes lodged in an artery within the brain, reducing blood flow and depriving brain cells of oxygen. Eighty-seven percent of strokes are ischemic.
In the course of examining the Drosophila tumor suppressor gene (Dlg), scientists at the Helmholtz Zentrum München have succeeded in decoding a new mechanism that regulates cell polarity in epithelial tissues or in neurons in the brain.
Prof. Heather Munroe-Blum, Principal and Vice-Chancellor of McGill University, and the Hon. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), welcome the news that Dr. Phil Gold is to be inducted into The Canadian Medical Hall of Fame. In 1965, Dr. Gold co-discovered the carcinoembryonic antigen (CEA), the first clinically useful human tumour marker that revolutionized the diagnosis and management of cancer.
Knowledge of 'movement routes' is the key to predicting the pattern of spread of infectious diseases of humans, and similar data could be crucial to understand animal disease risks, says team from the University of Edinburgh.
› Verified 4 days ago
| Entity Name | Weill Medical College Of Cornell |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669579017 PECOS PAC ID: 6800709023 Enrollment ID: O20040501000028 |
News Archive
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
Researchers at Vanderbilt University Medical Center are leading an international clinical trial to examine the functional benefits of a combined therapy to treat acute ischemic stroke, a type of stroke where a blood clot becomes lodged in an artery within the brain, reducing blood flow and depriving brain cells of oxygen. Eighty-seven percent of strokes are ischemic.
In the course of examining the Drosophila tumor suppressor gene (Dlg), scientists at the Helmholtz Zentrum München have succeeded in decoding a new mechanism that regulates cell polarity in epithelial tissues or in neurons in the brain.
Prof. Heather Munroe-Blum, Principal and Vice-Chancellor of McGill University, and the Hon. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), welcome the news that Dr. Phil Gold is to be inducted into The Canadian Medical Hall of Fame. In 1965, Dr. Gold co-discovered the carcinoembryonic antigen (CEA), the first clinically useful human tumour marker that revolutionized the diagnosis and management of cancer.
Knowledge of 'movement routes' is the key to predicting the pattern of spread of infectious diseases of humans, and similar data could be crucial to understand animal disease risks, says team from the University of Edinburgh.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason A Spector, MD 525 E 68th St, Box 115, New York, NY 10021-4870 Ph: (212) 746-5593 | Jason A Spector, MD 525 E 68th St, Suite M014, New York, NY 10021-4870 Ph: (212) 746-5593 |
News Archive
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.
Researchers at Vanderbilt University Medical Center are leading an international clinical trial to examine the functional benefits of a combined therapy to treat acute ischemic stroke, a type of stroke where a blood clot becomes lodged in an artery within the brain, reducing blood flow and depriving brain cells of oxygen. Eighty-seven percent of strokes are ischemic.
In the course of examining the Drosophila tumor suppressor gene (Dlg), scientists at the Helmholtz Zentrum München have succeeded in decoding a new mechanism that regulates cell polarity in epithelial tissues or in neurons in the brain.
Prof. Heather Munroe-Blum, Principal and Vice-Chancellor of McGill University, and the Hon. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), welcome the news that Dr. Phil Gold is to be inducted into The Canadian Medical Hall of Fame. In 1965, Dr. Gold co-discovered the carcinoembryonic antigen (CEA), the first clinically useful human tumour marker that revolutionized the diagnosis and management of cancer.
Knowledge of 'movement routes' is the key to predicting the pattern of spread of infectious diseases of humans, and similar data could be crucial to understand animal disease risks, says team from the University of Edinburgh.
› Verified 4 days ago
Dr. Brad Michael Gandolfi, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 905 5th Ave Ste 1c, New York, NY 10021 Phone: 212-287-7211 Fax: 212-287-7210 | |
Alexes Hazen, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 535 5th Ave Fl 29, New York, NY 10017 Phone: 917-301-6563 Fax: 347-407-8652 | |
Dr. Richard James Coburn, DMD MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 880 Fifth Avenue, New York, NY 10021 Phone: 212-288-5100 Fax: 212-472-2216 | |
Dr. Thomas W Loeb, Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 994 5th Ave, New York, NY 10028 Phone: 212-327-3700 Fax: 212-327-4506 | |
Jack Francis Woods, Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: Mskcc, 1275 York Avenue, New York, NY 10065 Phone: 917-375-5135 | |
Mihye Choi, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 305 E 47th St, Suite 1a, New York, NY 10017 Phone: 212-263-6004 Fax: 212-263-6319 | |
Dr. Robert Johnson Allen Jr., MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1275 York Ave # Mri1007, New York, NY 10065 Phone: 212-639-6131 Fax: 212-717-3677 |